Monday, December 09, 2019
IRST - Meldola
 
Help and contacts

IRST IRCCS
Via P. Maroncelli, 40
47014 Meldola (FC) Italy


How to reach us

e-mail: info@irst.emr.it

phone: +39 0543 739100

Research areas


Italian version

Research

Progress in the fight against cancer can be made if a close connection is maintained between care and research activities. For this reason IRST strives constantly to strengthen its scientific research at all levels in the areas of clinical care (aimed at the development of new diagnostic and therapeutic solutions), organizational healthcare (experimentation of innovative care models enabling the optimization of  available resources) and biomedical-translational research (immediate transfer of laboratory results to a clinical setting). The evolution in technology has led to a significant increase in research possibilities in the field of oncology and has substantially reduced the time needed to implement the results of basic research into clinical practice.

Research is of primary importance for IRST, as confirmed by its official recognition as a Cancer Institute (IRCCS) by the Italian Ministry of Health.  Specific areas of interest are as follows:

  • Epidemiology: data obtained on incidence/prevalence/survival enable surveillance and prevention activities to be performed;
  • Palliative care: essential for the maintenance of high-level care in far advanced stages of cancer;
  • Biomolecular research: identification of biological and predictive markers that can be used for  early diagnosis, risk classification, prognosis of solid tumors, treatment personalization and development of new drugs;
  • Translational research: direct transfer of the results of laboratory research to clinical practice  (from bench to beside);
  • Clinical research: execution of clinical studies on cancer in full compliance with national and international norms.
The Unit of Biostatistics and Clinical Trials is involved in all areas of research at the institute, participating in the planning and implementation of clinical studies, in ensuring that they are carried out correctly, and in the monitoring and processing of data.
Basic research - aimed at increasing our knowledge of molecular processes at the basis of biological phenomena, this type of research is the starting point for all subsequent investigations and is conducted mainly at a theoretical and practical (laboratory) level.
 
Preclinical research - the research phase in which researchers, before evaluating the effects of a new treatment in a clinical setting, verify its efficacy and, in particular, its safety for the patient. This type of research is key to the development of new drugs, equipment or therapeutic approaches. It involves intensive experimental in vitro and in vivo (based on the use of cells grown in the laboratory or using animal models) projects carried out under strict supervision and according to well-defined national and international regulations.
 
Translational research - verifies the possibility of transferring discoveries made in the laboratory to clinical practice for the direct benefit of patients. Its aim is to build a "bridge" connecting multiple scientific fields (biology, physics, chemistry, medicine) to promote a direct and continuous exchange of information.  This area represents the best and most effective integration between research and care activities.
 
Clinical research - the last stage of scientific research prior to the approval of a new drug or treatment. Clinical trials are divided into phases and involve patients.  They are carried out in strict adherence to principles of relevance, ethical feasibility and methodological correctness.
 
Epidemiological research - examines the distribution and frequency of diseases and important health issues within the population and evaluates risk factors for their onset and existing correlation with lifestyle, analysing possible causes, natural history of the disease, and consequences. Epidemiology also analyses the effectiveness of preventive tests and screening for early detection. In recent years, in oncology, genetic analyses have proven a valuable source of information for such studies.
 
Four lines of research characterizing the Institute as a Cancer Center (IRCCS) for the Ministry of Health have been identified:
  • Line 1 - Appropriateness, outcomes, drug value and organizational models for the continuity of diagnostic-therapeutic pathways in oncology;
  • Line 2 - Innovative therapies, phase I-III clinical trials and therapeutic strategy trials based on preclinical models, onco-immunological mechanisms and nanovectors;
  • Line 3 - Precision, gender and ethnicity-based medicine and geroscience: genetic-molecular mechanisms in the development, characterization and treatment of tumors;
  • Line 4 - Genetics and environment in the development and progression of tumors and inhibitory mechanisms. Exposomics and primary and secondary prevention.
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l.
Sede legale: 47014 Meldola (FC) Via Piero Maroncelli, 40
Capitale Sociale interamente versato Euro 20.000.000,00 - R.E.A. 288572 (FC)
Reg. Imprese FC/Cod. Fisc./Partita IVA 03154520401
Tel. 0543 739100 - Fax 0543 739123
e-mail: info@irst.emr.it - internet: www.irst.emr.it
PEC: direzione.generale@irst.legalmail.it